ALK and non-small cell lung carcinoma: Within a cohort of 30 advanced EGFR/ALK-wild type NSCLC patients treated with anti-PD1/PD-L1, non-responders had a significantly higher expression of exosomal miR-320b, -320c and -320d than responders at baseline [134].